Produktinformation
Lifirafenib is a potent antitumor agent that inhibits the MAP kinase pathway. It binds to the ATP-binding pocket of BRAF and inhibits the phosphorylation of downstream target proteins, such as MEK1/2 and ERK1/2. This inhibition leads to decreased cell proliferation and increased apoptosis. Lifirafenib has been shown to decrease tumor size in patients with mutant melanoma and is active in inhibiting epidermal growth factor receptor (EGFR) signaling in vitro. Lifirafenib has also been shown to be an effective inhibitor of b-raf mutant cells in vitro. In addition, it has been shown to inhibit tumor growth by matrix effect and can be used as a treatment for various cancers including human CD4+ lymphoma cells. Lifirafenib is metabolized quickly by cytochrome P450 enzymes in the liver, which may cause drug interactions with other drugs metabolized through this pathway. Pharmacokinetic studies
Chemische Eigenschaften
Technische Anfrage zu: 3D-WHC09077 Lifirafenib
Wenn Sie ein Angebot anfordern oder eine Bestellung aufgeben möchten, legen Sie stattdessen die gewünschten Produkte in Ihren Warenkorb und fordern Sie dann ein Angebot oder eine Bestellung an aus dem Warenkorb. Es ist schneller, billiger und Sie können von den verfügbaren Rabatten und anderen Vorteilen profitieren.
